SCHEMBL2166578

SCHEMBL2166578

CC=CC1C(C(=O)OCCC)C1(C)C

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
TSHR P16473 1/20 0.39
HCAR2 Q8TDS4 1/20 0.34
PPM1B O75688 1/20 0.34
PTPN1 P18031 1/20 0.34
PPP1CC P36873 1/20 0.34
TDP1 Q9NUW8 3/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
ADRA2A P08913 1/20 0.32
CNR1 P21554 1/20 0.32
ATM Q13315 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2166576 1.00 LMNA (0.50) LMNATSHRHCAR2PPM1BPTPN1
SCHEMBL2169791 1.00 LMNA (0.50) LMNATSHRHCAR2PPM1BPTPN1
SCHEMBL3682017 0.90 LMNA (0.47) LMNATSHRHCAR2TDP1MEN1
SCHEMBL3682019 0.90 LMNA (0.47) LMNATSHRHCAR2TDP1MEN1
SCHEMBL28763121 0.88 LMNA (0.47) LMNATSHRTDP1MEN1KMT2A
SCHEMBL2170337 0.86 LMNA (0.67) LMNATSHRTDP1MEN1KMT2A
SCHEMBL2168536 0.86 LMNA (0.67) LMNATSHRTDP1MEN1KMT2A
SCHEMBL29246835 0.86 LMNA (0.67) LMNATSHRTDP1MEN1KMT2A
SCHEMBL2168541 0.86 LMNA (0.67) LMNATSHRTDP1MEN1KMT2A
SCHEMBL1150197 0.84 LMNA (0.51) LMNATSHRHCAR2PPM1BPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1970368-B1 METHOD FOR PRODUCING OLEFIN COMPOUND SUMITOMO CHEMICAL CO (JP) 2012-08-29 EP disclosed
US-7985872-B2 Method for producing olefin compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-07-26 US disclosed
CN-1934063-B Method for producing (2-formyl-1-alkenyl)cyclopropane compound SUMITOMO CHEMICAL CO 2010-12-15 CN disclosed
US-7700799-B2 Method for producing (2-formyl-1-alkenyl) cyclopropane compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-20 US disclosed
US-20090137839-A1 METHOD FOR PRODUCING (2-FORMYL-1-ALKENYL) CYCLOPROPANE COMPOUND SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2009-05-28 US disclosed
US-7498459-B2 Method for producing (1-alkenyl)cyclopropane compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-03 US disclosed
US-20090036620-A1 METHOD FOR PRODUCING OLEFIN COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-02-05 US disclosed
EP-1970368-A1 METHOD FOR PRODUCING OLEFIN COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-09-17 EP disclosed
US-20070197818-A1 Method for producing (1-alkenyl) cyclopropane compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-08-23 US disclosed
CN-1934063-A Method for producing (2-formyl-1-alkenyl)cyclopropane compound SUMITOMO CHEMICAL CO (JP) 2007-03-21 CN disclosed
EP-1728781-A1 PROCESS FOR PRODUCTION OF (1-ALKENYL)CYCLOPROPANES Sumitomo Chemical Company, Limited (JP) 2006-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137839-A1 METHOD FOR PRODUCING (2-FORMYL-1-ALKENYL) CYCLOPROPANE COMPOUND ACSL3, ACSL1, ARL1 LMNA 2696/4885TSHR 3074/4885HCAR2 748/4885
US-20070197818-A1 Method for producing (1-alkenyl) cyclopropane compound ACSL3, ARL1, ACSL1 LMNA 3763/4885TSHR 3751/4885HCAR2 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.